---
title: Observatory of Patients With Metastatic ProstAte Adenocarcinoma That is Resistant to Castration and Multi-LinE Strategies
nct_id: NCT03611686
overall_status: ACTIVE_NOT_RECRUITING
sponsor: University Hospital, Rouen
study_type: OBSERVATIONAL
primary_condition: Metastatic Prostate Adenocarcinoma
countries: France
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT03611686.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT03611686"
ct_last_update_post_date: 2025-03-24
last_seen_at: "2026-05-12T07:04:26.485Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Observatory of Patients With Metastatic ProstAte Adenocarcinoma That is Resistant to Castration and Multi-LinE Strategies

**NCT ID:** [NCT03611686](https://clinicaltrials.gov/study/NCT03611686)

## Key Facts

- **Status:** ACTIVE_NOT_RECRUITING
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 219
- **Lead Sponsor:** University Hospital, Rouen
- **Conditions:** Metastatic Prostate Adenocarcinoma
- **Start Date:** 2018-04-17
- **Completion Date:** 2026-04
- **CT.gov Last Update:** 2025-03-24

## Brief Summary

Evaluation the overall survival of patients with metastatic prostate adenocarcinoma resistant to castration

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** MALE
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Patient monitored for castration-resistant metastatic prostate
* Patients starting a first or second line treatment as part of castration resistance
* Patient not objecting to the study after reading the information letter
* Patient aged over 18 years

Exclusion Criteria:

* Patient monitored for non-metastatic prostate cancer
* Patient monitored for castration-nonresistant prostate cancer
* Patient not able to understand the information letter
```

## Arms

- **patient followed for metastatic prostate adenocarcinoma** — patient wil be followed for metastatic prostate adenocarcinoma during 3 years

## Interventions

- **Local chemotherapy** (DRUG) — Local chemotherapy will be administrated according to local recommendation

## Primary Outcomes

- **Number of alive patient** _(time frame: 3 years)_

## Secondary Outcomes

- **Number of alive patient disease free** _(time frame: 3 years)_

## Locations (1)

- Rouen University Hospital, Rouen, France

## Recent Field Changes (last 30 days)

- `locations.rouen university hospital|rouen||france` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT03611686.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT03611686*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*